HC Wainwright & Co. Downgrades Forma Therapeutics Hldgs to Neutral, Lowers Price Target to $20
Author: Benzinga Newsdesk | September 02, 2022 05:06am
HC Wainwright & Co. analyst Robert Burns downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Neutral and lowers the price target from $53 to $20.